About this trial
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.
Eligibility criteria
Qualifiers
Men 35-74 years old
No known diagnosis of prostate cancer
Life expectancy >10 years
Meet cohort A, B, or C criteria
Disqualifiers
Prior diagnosis or treatment of prostate cancer
Inability to undergo prostate MRI
Inability to receive MRI contrast agent
Trial design
Treatments tested in this trial
- Prostate cancer screening